CoreWeave Looks Broken
seekingalpha.com
Adial Pharmaceuticals, Inc.ADILNASDAQ
Loading
Alerts
Want to monitor ADIL?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor ADILWant to monitor ADIL?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor ADILAdial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company's landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported).